Onasemnogene Abeparvovec Treatment after Nusinersen in an Infant with Spinal Muscular Atrophy Type 1
Authors:
Open Access
- 31 December 2022
- journal article
- research article
- Published by Kurume Medical Journal in The Kurume Medical Journal
- Vol. 69 (3.4) , 255-259
Abstract
Summary: Background: Until recently, the treatment of spinal muscular atrophy (SMA) was limited to symptomatic treatment with no cure. Three innovative drugs, nusinersen, onasemnogene abeparvovec (OA), and risdiplam have been developed to treat SMA. Although the clinical trials for these drugs have demonstrated their efficacy, there is limited information on real world treatment strategies. In this study, we present a case of a male infant with SMA type 1 who underwent OA treatment after nusinersen treatment. Case presentation: At 4 months of age, the patient was diagnosed with SMA type 1. At 6 months of age, nusinersen treatment was initiated. His motor function improved, but the effect was limited; therefore, his parents requested gene replacement therapy. During the preparation for OA treatment, anti-adeno-associated virus 9 (AAV9) antibody tests repeatedly showed non-specific reactions, which delayed initiation of treatment. The patient was put on ventilator management after he caught a common cold. During this management, the anti-AAV9 antibody test results were negative. Furthermore, the patient showed increased transaminase levels just before OA treatment; however, since these gradually decreased without signs of liver failure, we started OA treatment at 13 months of age. Four months later, the patient began to sit without support and was weaned from non-invasive positive pressure ventilation, although nasogastric tube feeding remained partially necessary. Conclusion: We believe that the management of unstable SMA type 1 symptoms, anti-AAV9 antibody testing, and changes in transaminase levels will be helpful for other patients with SMA who require treatment.Keywords
This publication has 13 references indexed in Scilit:
- Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to goNeuromuscular Disorders, 2021
- Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophyJournal of Hepatology, 2021
- Impact of Age and Motor Function in a Phase 1/2A Study of Infants With SMA Type 1 Receiving Single-Dose Gene Replacement TherapyPediatric Neurology, 2019
- Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1Advances in Therapy, 2019
- Time Is Motor Neuron: Therapeutic Window and Its Correlation with Pathogenetic Mechanisms in Spinal Muscular AtrophyMolecular Neurobiology, 2018
- Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiersNature Communications, 2017
- Observational study of spinal muscular atrophy type I and implications for clinical trialsNeurology, 2014
- Spinal muscular atrophy: a motor neuron disorder or a multi‐organ disease?Journal of Anatomy, 2013
- Antisense-based therapy for the treatment of spinal muscular atrophyJournal of Cell Biology, 2012
- Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72 400 specimensEuropean Journal of Human Genetics, 2011